BIOCRYST PHARMACEUTICALS ($BCRX) posted quarterly earnings results for Q1 2026 on Wednesday, May 6th. The company reported earnings of -$0.03 per share, missing estimates of $0.05 by $0.08. The company also reported revenue of $156,410,000, beating estimates of $154,145,460 by $2,264,540.
You can see Quiver Quantitative's $BCRX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIOCRYST PHARMACEUTICALS Insider Trading Activity
BIOCRYST PHARMACEUTICALS insiders have traded $BCRX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $BCRX stock by insiders over the last 6 months:
- ALANE P BARNES (Chief Legal Officer) has made 0 purchases and 6 sales selling 354,663 shares for an estimated $2,866,286.
- THERESA HEGGIE sold 49,933 shares for an estimated $504,822
- MACHELLE SANDERS sold 9,600 shares for an estimated $68,544
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
BIOCRYST PHARMACEUTICALS Hedge Fund Activity
We have seen 146 institutional investors add shares of BIOCRYST PHARMACEUTICALS stock to their portfolio, and 158 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 15,827,186 shares (+inf%) to their portfolio in Q4 2025, for an estimated $123,452,050
- JANUS HENDERSON GROUP PLC added 7,310,745 shares (+7807.2%) to their portfolio in Q4 2025, for an estimated $57,023,811
- ALKEON CAPITAL MANAGEMENT LLC removed 5,464,021 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $42,619,363
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 5,159,742 shares (-98.7%) from their portfolio in Q4 2025, for an estimated $40,245,987
- ABERDEEN GROUP PLC added 4,127,077 shares (+451.7%) to their portfolio in Q1 2026, for an estimated $39,289,773
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 3,620,261 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $28,238,035
- MORGAN STANLEY removed 3,457,396 shares (-66.5%) from their portfolio in Q4 2025, for an estimated $26,967,688
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
BIOCRYST PHARMACEUTICALS Government Contracts
We have seen $776,431 of award payments to $BCRX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- BULK ORDER ORLADEYO FOR VETERAN CARE.: $382,300
- PHARM - ORLADEYO: $360,000
- BEROTRALSTAT HCL 150MG CAP,ORAL (ORLADEYO).: $34,130
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
BIOCRYST PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $BCRX stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BCRX stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 11/13.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
BIOCRYST PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $BCRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 01/30/2026
To track analyst ratings and price targets for BIOCRYST PHARMACEUTICALS, check out Quiver Quantitative's $BCRX forecast page.
BIOCRYST PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $BCRX recently. We have seen 2 analysts offer price targets for $BCRX in the last 6 months, with a median target of $22.5.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $13.0 on 01/30/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $32.0 on 12/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
